Shalom Auerbach Sells 100,000 Shares of OS Therapies Inc (NYSE:OSTX) Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction on Friday, February 14th. The stock was sold at an average price of $2.84, for a total transaction of $284,000.00. Following the completion of the transaction, the insider now directly owns 2,431,211 shares in the company, valued at $6,904,639.24. This represents a 3.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80.

OS Therapies Price Performance

Shares of OSTX opened at $1.86 on Thursday. OS Therapies Inc has a 1-year low of $1.58 and a 1-year high of $7.00. The company’s fifty day moving average price is $3.36 and its 200-day moving average price is $3.15.

Analyst Ratings Changes

OSTX has been the topic of several analyst reports. Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a report on Thursday, January 30th.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.